🥇 First rule of investing? Know when to save! Up to 55% off InvestingPro before BLACK FRIDAYCLAIM SALE

Thailand in Talks With Russian, Chinese Developers for Vaccines

Published 2020-10-09, 12:09 a/m
© Bloomberg. A heath worker injects the 'Gam-COVID-Vac', also known as 'Sputnik V', COVID-19 vaccine, developed by the Gamaleya National Research Center for Epidemiology and Microbiology and the Russian Direct Investment Fund (RDIF), into a patients arm during a post-registration phase trial at the City Clinic #46 in Moscow, Russia, on Wednesday, Sept. 23, 2020. The Russian Direct Investment Fund will sell 32 million doses of Sputnik V to Mexico, with deliveries starting in November, the sovereign wealth fund said in a statement. Photographer: Andrey Rudakov/Bloomberg

(Bloomberg) -- Thailand is in talks with several Chinese, Russian and U.K. vaccine developers to secure viable inoculations against the coronavirus as soon as they became available -- a key element in the country’s effort to reopen its tourism-reliant economy.

The Southeast Asian nation, which has contained the outbreak after becoming the first outside China to detect the virus, also expects to reach agreements with the University of Oxford and Covax, a World Health Organization-backed initiative, by the end of October, according to Nakorn Premsri, director of Thailand’s National Vaccine Institute. The government aims to secure the first batch of doses within three to six months of a vaccine becoming available, he said.

“We need to be proactive and look for every way we can to secure the vaccine quickly,” Nakorn said in a phone interview Thursday. “We have a huge risk for an outbreak because we don’t have a large number of cases,” leaving the population vulnerable if infections start to spread.

Thailand has been largely free of community transmission of the deadly virus, with only two known cases since the end of May. It has so far logged about 3,600 cases since it first detected the virus in January. But its economy has been battered by the hit from the pandemic to its exports and tourism sectors, its two key economic drivers.

Thailand is also pursuing its own vaccine research program, a move spurred by its failure to promptly get an adequate supply of shots during the 2009 flu pandemic, Nakorn said. The first phase of human trials of the locally developed inoculation is set to start as early as December, he said.

Other highlights from Nakorn’s interview:

  • Thailand will provide vaccines to its citizens for free, although health authorities are still drawing up a priority list
  • Front-line health workers and social service providers may be given priority
  • Vaccines will likely be compulsory in areas with active outbreak
  • The Thai government plans to increase its budget for the vaccine program to about 3 billion baht ($96.1 million), enough to inoculate 33 million, or about 50% of its population

©2020 Bloomberg L.P.

© Bloomberg. A heath worker injects the 'Gam-COVID-Vac', also known as 'Sputnik V', COVID-19 vaccine, developed by the Gamaleya National Research Center for Epidemiology and Microbiology and the Russian Direct Investment Fund (RDIF), into a patients arm during a post-registration phase trial at the City Clinic #46 in Moscow, Russia, on Wednesday, Sept. 23, 2020. The Russian Direct Investment Fund will sell 32 million doses of Sputnik V to Mexico, with deliveries starting in November, the sovereign wealth fund said in a statement. Photographer: Andrey Rudakov/Bloomberg

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.